Prodrugs and Targeted Delivery (inbunden)
Inbunden (Hardback)
Antal sidor
Wiley-VCH Verlag GmbH
Mannhold, Raimund (series ed.)/Kubinyi, Hugo (series ed.)/Folkers, Gerd (series ed.)/Mannhold, Raimund (series ed.)/Kubinyi, Hugo (series ed.)/Folkers, Gerd (series ed.)/Mannhold, Raimund (series ed.)/Kubinyi, Hugo (series ed.)/Folkers, Gerd (series ed.)
15 farbige Abbildungen
248 x 181 x 30 mm
1111 g
Antal komponenter
Prodrugs and Targeted Delivery (inbunden)

Prodrugs and Targeted Delivery

Towards Better ADME Properties

Inbunden Engelska, 2010-12-15
Specialorder (osäker tillgång). Skickas inom 11-20 vardagar.
Fri frakt inom Sverige för privatpersoner.
Finns även som
Visa alla 2 format & utgåvor
This topical reference and handbook addresses the chemistry, pharmacology, toxicology and the patentability of prodrugs, perfectly mirroring the integrated approach prevalent in today's drug design. It summarizes current experiences and strategies for the rational design of prodrugs, beginning at the early stages of the development process, as well as discussing organ- and site-selective prodrugs. Every company employing medicinal chemists will be interested in this practice-oriented overview of a key strategy in modern drug discovery and development.
Visa hela texten

Passar bra ihop

  1. Prodrugs and Targeted Delivery
  2. +
  3. P21 Ras the Hidden Target for Cancer-An in Silico Analysis

De som köpt den här boken har ofta också köpt P21 Ras the Hidden Target for Cancer-An in Sili... av Besetti Hemalatha (häftad).

Köp båda 2 för 2258 kr


Har du läst boken? Sätt ditt betyg »

Recensioner i media

"The book captures all the important aspects of prodrugs. It is well organized in that each chapter presents a specific topic with very little duplication of contents between chapters ... Given the fact that prodrugs are now increasingly integrated into early drug discovery, this type of book would be a valuable addition to the library of any drug discovery institution." (Journal of Medicinal Chemistry, 8 August 2011) "Every company employing medicinal chemists will be interested in this practice-oriented overview of a key strategy in modern drug discovery and development." (Pharmiweb, 16 February 2011)

Bloggat om Prodrugs and Targeted Delivery

Övrig information

Jarkko Rautio is professor of pharmaceutical chemistry and head of the multidisciplinary Pharmaceutical and Medicinal Chemistry (PMC) research group at the School of Pharmacy, University of Eastern Finland (formerly University of Kuopio), where he received his PhD in pharmaceutical chemistry in 2000. He subsequently carried out his postdoctoral studies at the University of Maryland, Baltimore, USA, and was a visiting scientist at GlaxoSmithKline, North Carolina, while also co-founding the American Association of Pharmaceutical Scientists (AAPS) Prodrug Focus Group in 2005. Professor Rautio's research focuses on chemistry-based methods, especially prodrugs, to overcome the liabilities of drugs.


List of Contributors. Preface. A Personal Foreword. Part One Prodrug Design and Intellectual Property. 1 Prodrug Strategies in Drug Design (Jarkko Rautio). 1.1 Prodrug Concept. 1.2 Basics of Prodrug Design. 1.3 Rationale for Prodrug Design. 1.4 History of Prodrug Design. 1.5 Recently Marketed Prodrugs. 1.6 Concluding Remarks. References. 2 The Molecular Design of Prodrugs by Functional Group (Victor R. Guarino). 2.1 Introduction. 2.2 The Prodrug Concept and Basics of Design. 2.3 Common Functional Group Approaches in Prodrug Design. 2.4 Conclusions. References. 3 Intellectual Property Primer on Pharmaceutical Patents with a Special Emphasis on Prodrugs and Metabolites (Eyal H. Barash). 3.1 Introduction. 3.2 Patents and FDA Approval Process. 3.3 Obtaining a Patent. 3.4 Conclusion. Part Two Prodrugs Addressing ADMET Issues. 4 Increasing Lipophilicity for Oral Drug Delivery (Majid Y. Moridani). 4.1 Introduction. 4.2 pKa, Degree of Ionization, Partition Coefficient, and Distribution Coefficient. 4.3 Prodrug Strategies to Enhance Lipid Solubility. 4.4 Prodrug Examples for Antibiotics. 4.5 Antiviral Related Prodrugs. 4.6 Cardiovascular Related Prodrugs. 4.7 Lipophilic Prodrugs of Benzamidine Drugs. 4.8 Miscellaneous Examples. 4.9 Summary and Conclusion. References. 5 Modulating Solubility Through Prodrugs for Oral and IV Drug Delivery (Victor R. Guarino). 5.1 Introduction. 5.2 Basics of Solubility and Oral/IV Drug Delivery. 5.3 Prodrug Applications for Enhanced Aqueous Solubility. 5.4 Challenges with Solubilizing Prodrugs of Insoluble Drugs. 5.5 Additional Applications of Prodrugs for Modulating Solubility. 5.6 Parallel Exploration of Analogues and Prodrugs in Drug Discovery (Commentary). 5.7 Conclusions. References. 6 Prodrugs Designed to Target Transporters for Oral Drug Delivery (Mark S. Warren and Jarkko Rautio). 6.1 Introduction. 6.2 Serendipity: An Actively Transported Prodrug. 6.3 Requirements for Actively Transported Prodrugs. 6.4 Peptide Transporters: PEPT1 and PEPT2. 6.5 Monocarboxylate Transporters. 6.6 Bile Acid Transporters. 6.7 Conclusions. References. 7 Topical and Transdermal Delivery Using Prodrugs: Mechanism of Enhancement (Kenneth Sloan, Scott C. Wasdo, and Susruta Majumdar). 7.1 Introduction. 7.2 Arrangement of Water in the Stratum Corneum. 7.3 A New Model for Diffusion Through the Stratum Corneum: The Biphasic Solubility Model. 7.4 Equations for Quantifying Effects of Solubility on Diffusion Through the Stratum Corneum. 7.5 Design of Prodrugs for Topical and Transdermal Delivery Based on the Biphasic Solubility Model. 7.6 Comparison of Human and Mouse Skin Experiments. 7.7 Summary. References. 8 Ocular Delivery Using Prodrugs (Deep Kwatra, Ravi Vaishya, Ripal Gaudana, Jwala Jwala, and Ashim K. Mitra). 8.1 Introduction. 8.2 Criteria for an Ideal Ophthalmic Prodrug. 8.3 Anatomy and Physiology of the Eye. 8.4 Barriers to Ocular Drug Delivery. 8.5 Influx and Efflux Transporters on the Eye. 8.6 Transporter-Targeted Prodrug Approach. 8.7 Drug Disposition in Ocular Delivery. 8.8 Effect of Physiochemical Factors on Drug Disposition in Eye. 8.9 Prodrug Strategy to Improve Ocular Bioavailability (Nontransporter-Targeted Approach). 8.10 Recent Patents and Marketed Ocular Prodrugs. 8.11 Novel Formulation Approaches for Sustained Delivery of Prodrugs. 8.12 Conclusion. References. 9 Reducing Presystemic Drug Metabolism (Majid Y. Moridani). 9.1 Introduction. 9.2 Presystemic Metabolic Barriers. 9.3 Prodrug Approaches to Reduce Presystemic Drug Metabolism. 9.4 Targeting Colon. 9.5 Targeting Lymphatic Route. 9.6 Conclusion. References. 10 Enzyme-Activated Prodrug Strategies for Site-Selective Drug Deli